Tranquility Partners LLC reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 8.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,628 shares of the medical research company’s stock after selling 1,469 shares during the period. IQVIA accounts for about 1.6% of Tranquility Partners LLC’s investment portfolio, making the stock its 12th largest position. Tranquility Partners LLC’s holdings in IQVIA were worth $3,847,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of IQV. AdvisorNet Financial Inc boosted its position in shares of IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares during the last quarter. BKM Wealth Management LLC acquired a new stake in shares of IQVIA in the fourth quarter worth approximately $32,000. Activest Wealth Management acquired a new stake in shares of IQVIA in the fourth quarter worth approximately $35,000. CVA Family Office LLC acquired a new stake in shares of IQVIA in the fourth quarter worth approximately $43,000. Finally, Live Oak Investment Partners acquired a new stake in shares of IQVIA in the fourth quarter worth approximately $41,000. 89.62% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Insiders sold a total of 41,285 shares of company stock valued at $10,331,003 over the last 90 days. 1.60% of the stock is owned by company insiders.
Analysts Set New Price Targets
Read Our Latest Research Report on IQV
IQVIA Stock Down 0.8 %
Shares of NYSE:IQV traded down $1.88 during midday trading on Wednesday, reaching $227.26. The company had a trading volume of 705,876 shares, compared to its average volume of 973,666. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The stock’s fifty day moving average price is $244.16 and its 200-day moving average price is $221.33. The stock has a market capitalization of $41.25 billion, a P/E ratio of 31.43, a PEG ratio of 2.24 and a beta of 1.50. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73.
IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. The business had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.54 earnings per share. Equities research analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.
IQVIA Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
- Five stocks we like better than IQVIA
- Ride Out The Recession With These Dividend Kings
- United Airlines Soars on Earnings Beat
- What is a Low P/E Ratio and What Does it Tell Investors?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.